NCT01189526

Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)

A Randomized Trial Comparing Intravitreal Ranibizumab and Macular Laser Photocoagulation for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Seoul Retina Investigator Group · Network
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the efficacy of intravitreal Ranibizumab in comparison with macular laser photocoagulation as treatments for macular edema secondary to branch retinal vein occlusion. Characteristics of this study is as below 1. Multicenter, randomized clinical trial. (intravitreal Ranibizumab 0.5mg injection vs. macular laser photocoagulation) 2. After 48 weeks follow up, functional change(visual acuity)and anatomical change (central retinal thickness) would be evaluated

Conditions

• Branch Retinal Vein Occlusion

Interventions

Type	Name	Description
DRUG	Ranibizumab	Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
PROCEDURE	macular laser photocoagulation	Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.

Timeline

• Start date: 2009-01-01
• Primary completion: 2010-08-01
• Completion: 2011-08-01
• First posted: 2010-08-26
• Last updated: 2010-08-26

Locations

1 site across 1 country: South Korea